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ABSTRACT
Background. Administration of ferric pyrophosphate citrate
(FPC, Triferic™) via hemodialysate may allow replacement of
ongoing uremic and hemodialysis-related iron losses. FPC do-
nates iron directly to transferrin, bypassing the reticuloendo-
thelial system and avoiding iron sequestration.
Methods.Two identical Phase 3, randomized, placebo-controlled
trials (CRUISE 1 and 2) were conducted in 599 iron-replete
chronic hemodialysis patients. Patients were dialyzed with dialys-
ate containing 2 µM FPC-iron or standard dialysate (placebo) for
up to 48 weeks. Oral or intravenous iron supplementation was
prohibited, and doses of erythropoiesis-stimulating agents were
held constant. The primary efﬁcacy end point was the change
in hemoglobin (Hgb) concentration from baseline to end of
treatment (EoT). Secondary end points included reticulocyte
hemoglobin content (CHr) and serum ferritin.
Results. In both trials, Hgb concentration was maintained from
baseline to EoT in the FPC group but decreased by 0.4 g/dL in
the placebo group (P < 0.001, combined results; 95% conﬁdence
interval [CI] 0.2–0.6). Placebo treatment resulted in signiﬁcant-
ly larger mean decreases from baseline in CHr (−0.9 pg versus
−0.4 pg, P < 0.001) and serum ferritin (−133.1 µg/L versus
−69.7 µg/L, P < 0.001) than FPC treatment. The proportions
of patients with adverse and serious adverse events were similar
in both treatment groups.
Conclusions. FPC delivered via dialysate during hemodialysis
replaces iron losses, maintains Hgb concentrations, does not
increase iron stores and exhibits a safety proﬁle similar to pla-
cebo. FPC administered by hemodialysis via dialysate repre-
sents a paradigm shift in delivering maintenance iron therapy
to hemodialysis patients.
Keywords: anemia, erythropoiesis-stimulating agent, ferric
pyrophosphate citrate, hemodialysis, iron
INTRODUCTION
In patients with hemodialysis-dependent Stage 5 chronic kidney
disease (CKD-5HD), iron needs are increased because of
elevated erythroid iron requirements resulting from the use of
erythropoiesis-stimulating agents (ESAs) and dialysis-associated
blood losses, including frequent blood sampling and overt or
occult gastrointestinal bleeding [1–3]. At the same time, iron
supply is suppressed by the chronic inﬂammation of renal failure,
which stimulates hepatic production of the systemic iron regula-
tory hormone, hepcidin [3, 4]. To counterbalance increased iron
losses and hepcidin-induced sequestration of iron,most hemodi-
alysis patients are currently administered intravenous (IV) iron
[5]. Intravenous ironmay increase the risks of inﬂammation, oxi-
dative stress, endothelial dysfunction, cardiovascular disease, im-
mune deﬁciency and bacterial infections [6] and further
exacerbate iron sequestration.
Ferric pyrophosphate citrate (FPC, Triferic™) is a
carbohydrate-free, water-soluble, complex iron salt that was
ﬁrst demonstrated to deliver iron via dialysate in 1999, allow-
ing maintenance of hemoglobin (Hgb) concentration and
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iron balance while reducing the need for IV iron by
about 80% [7].
FPC is added to liquid bicarbonate concentrate at the clinic.
The bicarbonate concentratewith FPC subsequentlymixes with
acid concentrate and water in the hemodialysis machine to gen-
erate dialysate containing 2 µM iron. FPC crosses the dialyzer
membrane, enters the blood, donates its iron directly to trans-
ferrin and is rapidly cleared from circulation. This provides for
iron utilization for erythropoiesis and avoids iron sequestration
within reticuloendothelial macrophages [7, 8], thereby avoiding
hepcidin-induced iron sequestration.
The Continuous Replacement Using Iron Soluble Equiva-
lents (CRUISE 1 and 2) studies tested the hypothesis that
FPC administered via dialysate can sustain iron delivery for
erythropoiesis and is more effective than placebo in maintain-
ing Hgb concentration in hemodialysis.
MATERIALS AND METHODS
Two identical, prospective, randomized, single-blind (patients
blinded to treatment assignment), placebo-controlled, parallel-
group, multicenter, Phase 3 studies were conducted at 88 study
locations in the United States and Canada from March 2011 to
July 2013.
Study design
The studies consisted of a screening period, followed by
three sequential stages (Supplementary data, Figure S1): Stage
1, run-in (1–4 weeks, no study drug treatment); Stage 2, rando-
mized treatment (single-blind treatment for up to 48 weeks;
assessment of primary end point) and Stage 3, open-label treat-
ment (long-term safety study; results not reported here).
Patients who met criteria for entry into Stage 2 were rando-
mized in a 1:1 ratio to dialyze during every hemodialysis session
with FPC dialysate (2 µmoles [110 µg] iron/liter) or placebo
(standard dialysate). Randomization was stratiﬁed by pre-
randomization Hgb and baseline prescribed ESA dose (see
also Supplementary data, Methods).
Oral and IV iron products and changes in ESA product, dose
and route of administration were prohibited from screening
through the end of Stage 2 (randomized treatment). Patients
completed Stage 2 when (i) Hgb became <9.0 or >12.0 g/dL
conﬁrmed by a consecutive value obtained within 2 weeks,
(ii) ferritin was <100 µg/L conﬁrmed by a consecutive value
within 2 weeks, (iii) Hgb was >11.5 g/dL conﬁrmed by a con-
secutive value within 2 weeks, with an associated Hgb increase
of ≥1.0 g/dL over 4 weeks, or (iv) 48 weeks of treatment had
elapsed. Patients who completed Stage 2 (randomized treat-
ment) then transitioned to Stage 3 (open-label).
Study population
Patients 18 years or older who had received hemodialysis for
≥4 months using an arteriovenous (AV) ﬁstula or graft or tun-
neled internal jugular or subclavian catheter were enrolled in
Stage 1. Patients had received IV iron between 6 months and
2 weeks before enrollment and had a mean Hgb of 9.5–11.5
g/dL, serum ferritin of 200–800 µg/L and transferrin saturation
(TSAT) of 15–40%. ESA doses during the 4 weeks before enroll-
ment were ≤45 000 U/week epoetin or ≤200 μg/week darbe-
poetin. For inclusion in Stage 2, patients must have had a
mean Hgb of 9.5–11.5 g/dL over the three most recent consecu-
tive weekly measurements, with ≤1.0 g/dL difference between
maximum and minimum values.
Exclusion criteria included >800 mg IV iron within 8 weeks
or IV iron administration during 2 weeks before enrollment;
change in ESA administration route or >35% change in dose
during 2 weeks before screening; blood transfusion within 12
weeks before enrollment; serum albumin <3.0 g/dL within 8
weeks before enrollment; low serum folate or vitamin B12 at en-
rollment; active bleeding or scheduled surgery or concomitant
infection or inﬂammatory disorder other than CKD. Patients
who entered Stage 2 were not to have received IV iron in the
preceding 4 weeks or had any change in ESA dose during the
preceding 6 weeks.
Study procedures
Laboratory evaluations included every-mid-week pre-hemodi-
alysis Hgb; every-other-mid-week pre-hemodialysis ferritin, re-
ticulocyte hemoglobin content (CHr), C-reactive protein (CRP)
and serum iron panel; and monthly post-hemodialysis serum
iron panel (Supplementary data, Table S1). Treatment-emergent
adverse events (TEAEs), transfusions and concomitant medica-
tion use were recorded at each visit.
The studies were approved by an institutional review board
at each site and written informed consent was obtained from all
patients or authorized representatives.
Outcomes
The primary efﬁcacy end point was the mean change in Hgb
from baseline to end of treatment (EoT), deﬁned as the last one-
sixth of time in the randomized stage (Stage 2) (average of all
Hgb values obtained in the window) per patient. The secondary
efﬁcacy end points included mean change in Hgb from baseline
every 4 weeks; mean change from baseline in ferritin, CHr,
serum iron and TSAT every 4 weeks and at EoT; and mean in-
tradialytic change from pre-hemodialysis to post-hemodialysis
in serum iron, unsaturated iron-binding capacity (UIBC) and
TSAT (see Supplementary data, deﬁnition/calculation of se-
lected laboratory end points).
Safety end points included the incidence of intradialytic
hypotension (IDH) and incidence and severity of TEAEs.
Statistical analysis
Each trial was designed to detect, with 90% power, a statis-
tically signiﬁcant treatment difference in Hgb change from
baseline between FPC and placebo. The determined sample
size of 133 per treatment group per study was increased to
150 per treatment group to allow for early terminations unre-
lated to iron maintenance or study drug treatment.
The modiﬁed intent-to-treat (MITT) population (rando-
mized patients who received at least one dose of study drug
and had at least one post-baseline Hgb value) was used for
the efﬁcacy analyses. Safety analyses were conducted on the
safety population (all patients who received any randomized
study drug).
O
R
IG
IN
A
L
A
R
T
IC
L
E
2020 S.N. Fishbane et al.
All statistical comparisons were performed using two-sided
tests at the α = 0.05 signiﬁcance level and were not adjusted for
multiple comparisons. The last post-baseline observation car-
ried forward (LOCF) method was used if imputation was per-
formed for an efﬁcacy parameter. The primary end point was
analyzed using an analysis of covariance model, with mean
change in Hgb from baseline to EoT as the response variable,
treatment group as the factor and baseline Hgb as the covariate.
Secondary end points were analyzed using the Wilcoxon rank-
sum test and Fisher’s exact test for proportions. All analyses
were produced using SAS® statistical software version 9.1.3 or
higher (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patients
A total of 599 patients were enrolled; 290 were randomized
to FPC and 295 were randomized to placebo (MITT popula-
tion; Figure 1). Mean age was 57.1 years and 59.6 years in the
FPC and placebo groups, respectively (Table 1). Men consti-
tuted the majority in both treatment groups. Most patients
(>85%) in both groups had undergone hemodialysis for >1
year. No signiﬁcant differences were observed between groups
in relevant laboratory values, medication histories or other
characteristics at baseline.
Patients completed Stage 2 when they met one of the three
criteria for a protocol-mandated change in anemia manage-
ment (primarily high or low Hgb, necessitating ESA dose
change), and this accounted for completion of Stage 2 in 137
(45.8%) of FPC-treated patients and 172 (57.3%) of placebo-
treated patients (Figure 1 and Supplementary data, Table S2).
ﬁfty-ﬁve FPC-treated patients (18.4%) and 49 placebo-treated
patients (16.3%) completed Stage 2 by reaching 48 weeks of ran-
domized treatment without meeting criteria for a protocol-
mandated change in anemia management (Figure 1). Similar
percentages in each group transitioned to Stage 3 (FPC,
66.6%; placebo, 73.7%). In total, 35.8 and 26.3% of FPC-treated
and placebo-treated patients discontinued from Stage 2 of the
studies; all were included in the intention-to-treat analyses.
The proportions of patients who required protocol-mandated
changes in ESA dose were similar in the FPC (43.5%) and pla-
cebo (46.0%) groups, but the indications for change differed
(Supplementary data, Table S2). Among these patients, an in-
crease in Hgb to >12.0 g/dL led to protocol-mandated decreases
in ESA dose in 55.4% of FPC-treated patients as compared with
38.4% of placebo-treated patients (P = 0.007), a difference con-
sistent with improved delivery of iron for erythropoiesis by
FPC relative to placebo. A decrease in Hgb to <9.0 g/dL led to
protocol-mandated increases in ESA dose in 43.5% of patients
receiving placebo compared with 30.0% of those receiving FPC
(P = 0.02), a divergence suggesting improved delivery of iron
for erythropoiesis by FPC relative to placebo.
Intervention
A total of 292 FPC-treated and 296 placebo-treated patients
received at least one dose of study drug. Mean and median
durations of exposure to study drug in Stage 2 were 159.4 and
128.0 days, respectively, in the FPC group and 161.4 and 143.0
days, respectively, in the placebo group.
Primary and secondary outcomes
FPC met the primary efﬁcacy end point, with a treatment
difference of 0.4 g/dL in favor of FPC in the mean change in
Hgb from baseline to EoT (P = 0.011 for individual studies,
95% conﬁdence interval [CI] 0.1–0.6; P < 0.001 for combined
results, 95% CI 0.2–0.6) (Table 2). During Stage 2, mean
Hgb values remained stable in the combined FPC group
and decreased in the combined placebo group (Figure 2a).
Results were consistent between studies (Supplementary
data, Figure S2). An intent-to-treat population analysis (FPC,
N = 299; placebo, N = 300) was also performed, and results
were similar, with a treatment difference of 0.4 g/dL in favor
of FPC for the mean change in Hgb from baseline to EoT
(P = 0.010 for individual studies, 95% CI 0.1–0.6; P < 0.001
for combined results, 95% CI 0.2–0.5). Additional sensitivity
analyses of the combined study data, which were performed
by incorporating all data points via mixed-model repeated-
measures analysis, provided similar results (Supplementary
data, Table S3), as did an analysis of patients who withdrew
for protocol-mandated changes in anemia management
(Supplementary data, Table S4).
Themean change frombaseline in serum ferritin fromEoTwas
signiﬁcantly smaller in the combined FPC group (−69.7 µg/L,
95% CI −87.2 to −52.2) than in the combined placebo group
(−133.1 µg/L, 95% CI −159.9 to −106.3), as well as signiﬁcantly
smaller in the FPC group than in the placebo group in each of
the studies (Supplementary data, Figure S3). The mean difference
between the FPC and placebo groups for the combined studieswas
63.4 µg/L at EoT (95% CI 31.3–95.5, P < 0.001), with signiﬁcant
differences observed between groups at each time point beginning
at week 5 (Figure 2b). Mean differences between FPC and placebo
were 70.8 µg/L in CRUISE 1 and 55.6 µg/L in CRUISE 2 at EoT
(P < 0.001 for both comparisons), with signiﬁcant differences ob-
served between groups beginning at week 5 in both studies.
The mean (±SD) change from baseline in CHr from baseline
at EoT was signiﬁcantly smaller in the combined FPC group
than in the combined placebo group (−0.4 ± 1.3 pg versus
−0.9 ± 1.4 pg, P < 0.001) (Figure 2c). Results were consistent
between studies (Supplementary data, Figure S4). Similarly,
the mean change from baseline in pre-hemodialysis serum iron
at EoT was signiﬁcantly smaller in the combined FPC group
than in the combined placebo group (−1.3 ± 23.1 µg/dL versus
−6.7 ± 19.7 µg/dL, P = 0.008) (Figure 2d). The mean change
from baseline in pre-hemodialysis TSAT at EoT was also
signiﬁcantly smaller in the combined FPC group than in
the combined placebo group (−1.0 ± 8.4% versus −3.2 ± 7.8%,
P = 0.002) (Figure 2e).
The mean change in serum iron from pre-hemodialysis to
post-hemodialysis was larger in the combined FPC group
(+104.6 ± 41.6 µg/dL) than in the combined placebo group
(+4.6 ± 17.4 µg/dL) (Figure 3). Likewise, a marked increase
in mean TSAT from pre-hemodialysis to post-hemodialysis
(+35.4 ± 13.4%) was observed in the combined FPC group
but not in the combined placebo group (−0.4 ± 5.2%). Mean
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UIBC decreased (by −71.2 ± 31.6 µg/dL) from pre-hemodialysis
to post-hemodialysis in the combined FPC group to a post-
hemodialysis value of 102.3 ± 39.8 µg/dL but did not change sig-
niﬁcantly in the combined placebo group (+14.9 ± 17.9 µg/dL).
Post-dialysis serum iron, TSAT and UIBC values returned to
baseline by the time of the next hemodialysis session.
A minority of patients received transfusions (prohibited
during randomized stage), leading to study withdrawal. Fewer
patients in the combined FPC group (9 patients, 20 units)
than in the combined placebo group (23 patients, 48 units)
received transfusions (P < 0.02) (Supplementary data,
Table S5). This result is consistent with better maintenance of
Hgb in the FPC group.
Adverse events
The majority of patients in both groups experienced at least
one TEAE (combined FPC, 78.4%; combined placebo, 75.3%;
Supplementary data, Table S6). Drug-related TEAEs were re-
ported in 7.5 and 4.1% of the combined FPC and combined pla-
cebo groups, respectively. None of the serious TEAEs (reported
F IGURE 1 : Patient disposition—CONSORT diagram. ESA, erythropoiesis-stimulating agent; FPC, ferric pyrophosphate citrate; Hgb,
hemoglobin; IV, intravenous; MITT, modiﬁed intent to treat.
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in 27.7 and 27.4% of patients in combined FPC and combined
placebo groups, respectively) was considered related to study
drug. Among patients with TEAEs leading to study discontinu-
ation (combined FPC, 13; combined placebo, 7), events were
considered treatment-related in 7 and 0 of the FPC-treated
and placebo-treated patients, respectively. Sixteen deaths (com-
bined FPC, 10; combined placebo, 6) led to study discontinu-
ation (Figure 1); none was considered related to study drug.
The most common TEAEs in the combined FPC group were
experienced by similar proportions of FPC-treated and
placebo-treated patients (Supplementary data, Table S7). The
most frequently reported TEAE in both groups was procedural
hypotension (primarily IDH, Supplementary data, Table S8),
which occurred in 21.6% of FPC-treated patients and 19.3%
of placebo-treated patients. Other frequently reported events
were AV ﬁstula site complication, muscle spasms, headache
and diarrhea. One non-serious case of suspected hypersensitiv-
ity was reported (as IDH) in one FPC-treated patient (see Sup-
plementary data, brief summary of case of suspected
hypersensitivity); review of the case suggested that the event
was likely due to hypovolemia. No clinically meaningful differ-
ences were observed between groups in the incidence of TEAEs
of special interest [data not shown].
DISCUSSION
The primary objective of these studies was to demonstrate that
FPC administered via dialysate is more effective than placebo in
maintaining Hgb concentration in chronic hemodialysis
patients. FPC maintained Hgb from baseline to EoT, and the
primary efﬁcacy end point of the mean change in Hgb from
baseline to EoT favored FPC by 0.4 g/dL (P < 0.001). This ob-
servedmagnitude of difference inHgb concentrations between the
two groups was constrained by the study design, which limited
changes in Hgb in all patients to within predeﬁned safe upper
and lower limits. Since the ESA dose was clamped and
iron supplementation was prohibited during the randomized
treatment stage, the CRUISE study design allowed completion of
the randomized treatment stage and transition to the open-label
stage if a patient required a protocol-mandated change in anemia
management (Hgb < 9.0 or >12 g/dL or ferritin <100 µg/L).
The study population was iron-replete at the time of
enrollment as reﬂected by an average serum ferritin level of
about 500 µg/L. In hemodialysis patients, serum ferritin con-
centrations reﬂect the magnitude of body iron stores and the ef-
fects of chronic inﬂammation secondary to renal failure.
Table 1. Baseline demographics, Stage 2 (MITT population)
CRUISE 1 and 2 combined
Variablea FPC
(N = 290)
Placebo
(N = 295)
Age (years) 57.1 ± 12.5 59.6 ± 13.7
Sex
Male 177 (61.0%) 195 (66.1%)
Female 113 (39.0%) 100 (33.9%)
Race
White 153 (52.8%) 165 (55.9%)
Black 111 (38.3%) 99 (33.6%)
Other 26 (9.0%) 31 (10.5%)
Primary cause of CKD
Diabetes 148 (51.0%) 145 (49.2%)
Hypertension 164 (56.6%) 145 (49.2)
Received hemodialysis for >1 year 253 (87.2%) 259 (87.7%)
History of cardiovascular risk factors and inﬂammatory conditions
Heart failure 90 (31.0%) 71 (24.1%)
Diabetes 183 (63.1%) 180 (61.0%)
Coronary artery disease 104 (35.9%) 116 (39.3%)
Cerebrovascular accident 34 (11.7%) 45 (15.3%)
Peripheral vascular disease 44 (15.2%) 44 (14.9%)
Permanent catheter for dialysis
vascular access
28 (9.7%) 30 (10.2%)
Whole blood Hgb (g/dL) 11.0 ± 0.6 10.9 ± 0.6
Serum iron (μg/dL) 66.1 ± 21.5 65.3 ± 22.0
Serum TSAT (%) 28.0 ± 8.2 27.6 ± 8.2
Ferritin (µg/L) 511.5 ± 197.4 495.9 ± 206.0
CHr (pg) 32.5 ± 2.1 32.6 ± 1.9
Serum transferrin (g/L) 1.9 ± 0.3 1.9 ± 0.3
Serum albumin (g/dL) 4.1 ± 0.3 4.1 ± 0.3
High-sensitivity CRP (nmol/L) 78.7 ± 100.3 86.1 ± 162.1
Post-hemodialysis weight (kg) 85.2 ± 22.6 84.2 ± 22.8
Previous intravenous iron therapy 226 (77.9%) 237 (80.3%)
Previous oral iron therapy 6 (2.1%) 6 (2.0%)
Prior hypersensitivity to intravenous iron 1 (0.3%) 1 (0.3%)
Median dose of intravenous iron (mg/2 mo) 375 350
Days since last intravenous iron therapy 64.5 ± 29.2 65.9 ± 27.7
Current ESA use 285 (98.3%) 290 (98.3%)
Median ESA dose in epoetin equivalents
(units/wk)
6600 6600
ESA, erythropoiesis-stimulating agent; FPC, ferric pyrophosphate citrate; MITT, modiﬁed
intent to treat; NA, not applicable.
aUnless otherwise noted, values are reported as mean ± SD.
Table 2. Change from baseline in Hgb at EoT in Stage 2 (MITT population)
CRUISE 1 CRUISE 2 Combined
FPC (N = 148) Placebo (N = 151) FPC (N = 142) Placebo (N = 144) FPC (N = 290) Placebo (N = 295)
Baseline Hgb (g/dL), mean ± SD 11.0 ± 0.6 10.9 ± 0.6 11.0 ± 0.6 10.9 ± 0.6 11.0 ± 0.6 10.9 ± 0.6
End-of-treatment Hgb (g/dL), mean ± SD 10.9 ± 1.3 10.5 ± 1.4 10.9 ± 1.4 10.5 ± 1.3 10.9 ± 1.3 10.5 ± 1.3
Change from baseline (g/dL), mean ± SD −0.0 ± 1.2 −0.4 ± 1.3 −0.1 ± 1.2 −0.4 ± 1.2 −0.1 ± 1.2 −0.4 ± 1.2
ANCOVA with baseline Hgb as covariate
LS mean change from baseline (g/dL) ± SE 0.1 ± 0.1 −0.3 ± 0.1 −0.0 ± 0.1 −0.4 ± 0.1 0.0 ± 0.1 −0.4 ± 0.1
95% CI of LS mean −0.2, 0.3 −0.5, −0.1 −0.3, 0.2 −0.6, −0.2 −0.2, 0.2 −0.5, −0.2
LS mean difference (FPC-placebo) ± SE 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1
95% CI of LS mean 0.1, 0.6 0.1, 0.6 0.2, 0.6
P-value 0.011 0.011 < 0.001
ANCOVA, analysis of covariance; CI, conﬁdence interval; FPC, ferric pyrophosphate citrate; Hgb, hemoglobin; LS, least squares; MITT, modiﬁed intent to treat.
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Because neither group had evidence of signiﬁcant changes in
inﬂammation based on lack of signiﬁcant change in CRP dur-
ing the course of the study, changes in serum ferritin most likely
reﬂected changes in body iron stores. The placebo group experi-
enced decline in serum ferritin due to depletion of iron stores, as
a consequence of ongoing uremic- and hemodialysis-associated
losses. FPC generally conserved serum ferritin (Figure 2b), indi-
cating that FPC effectively replaced the uremic and gastrointes-
tinal losses that average about 5−7 mg iron per hemodialysis
treatment. Fewer FPC-treated patients than placebo-treated pa-
tients required a protocol-mandated change in anemia
management for a serum ferritin <100 µg/L (3 versus 13% re-
spectively, P < 0.001; Supplementary data, Table S2), indicating
that, in actual clinical practice, only a small proportion of patients
receiving FPC are likely to experience iron losses that exceed the
supply from FPC-iron and will require occasional additional
supplementation with IV iron. Notably, with regular administra-
tion of FPC, the average serum ferritin level did not exceed base-
line values, demonstrating that patients did not develop iron
overload. Therefore, maintenance of iron therapy using FPC pre-
vents depletion of iron stores, without causing iron overload, in
iron-replete hemodialysis patients.
F IGURE 2 : Mean change in Hgb concentration (A), ferritin concentration (B), CHr (C), serum iron concentration (D) and TSAT (E) from
baseline during Stage 2-CRUISE 1 and 2 studies combined (MITT population). Values other than EoT are based on an LOCFanalysis. Bars indicate
SEM. For Hgb, P-value is from an analysis of covariance with baseline Hgb as the covariate. For all other parameters, P-value is from a Wilcoxon
rank-sum test. CHr, reticulocyte Hgb content; EoT, end of treatment; Fe, iron; FPC, ferric pyrophosphate citrate; Hgb, hemoglobin; LOCF, last
post-baseline observation carried forward; MITT, modiﬁed intent to treat (FPC, N = 290; placebo, N = 295); TSAT, transferrin saturation.
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The intradialytic increase in serum iron and concomitant
decrease in UIBC (Figure 3) indicate uptake of FPC-iron by
available binding sites on transferrin. The substantial elevation
in TSAT during dialysis indicates a greatly increased proportion
of diferric transferrin. Diferric transferrin transports twice as
much iron as the monoferric form and has a higher afﬁnity
for the transferrin receptor, thereby enhancing the efﬁciency
of iron delivery to erythroid precursors [9]. The FPC-iron
bound to transferrin is cleared rapidly from the circulation,
with TSAT returning to baseline by the next dialysis [7]. This
is in contrast to IV iron, which is approved for periodic reple-
tion of iron stores in iron-deﬁcient hemodialysis patients. Intra-
venous iron in 50−100 mg doses is often infused over a few
minutes, generating non-transferrin-bound iron, oxidative
stress and endothelial dysfunction [10, 11].
TEAEs, including serious TEAEs, were similar in the groups
(Supplementary data, Table S7) and were consistent with those
anticipated in CKD-5HD patients. Measurement of indicators
of inﬂammation (CRP) and nutrition (albumin, transferrin)
showed no signiﬁcant changes in the FPC group. The numerical
imbalance in the number of deaths in the FPC and placebo
groups (Figure 1) is likely secondary to a relatively small sample
size since the mortality rate for FPC (6.5 deaths/100 patient-
years of exposure [PYE]) in the pooled phase 2 and 3 studies
(>1400 patients, representing 780 patient-years of exposure)
is similar to the placebo rate (7.2/100 PYE) from recent con-
trolled studies [12]. Neither anaphylaxis nor an increase in
the frequency or severity of IDH was observed with FPC.
Other IV iron complexes have been rarely associated with
hypersensitivity reactions, including anaphylaxis, anaphylac-
toid reaction and angioedema, which may be associated with
the carbohydrate moiety [13]. FPC is a carbohydrate-free
iron salt, which may account for the lack of anaphylactic
reactions to date.
Although demonstrating that FPC-iron administered via
dialysate is able to maintain Hgb concentration, our studies
have limitations. Our data may not be generalizable to all
types of patients on maintenance hemodialysis. For example,
patients with larger blood losses may develop iron deﬁciency
and require supplemental administration of IV iron for reple-
tion of stores. Furthermore, this study did not reﬂect current
clinical practice, which is characterized by frequent ESA dose
adjustments and supplemental IV iron to maintain Hgb.
These changes had to be prohibited in this study to isolate
the effects of FPC on Hgb and demonstrate that the placebo
group could develop iron-restricted erythropoiesis while FPC
maintained Hgb concentrations.
In conclusion, our studies demonstrate that regular admin-
istration of FPC during hemodialysis by addition to the hemo-
dialysis solution is well tolerated and effectively replaces
ongoing dialytic and uremic iron losses, thereby maintaining
iron balance and Hgb concentration. Maintenance iron therapy
using FPC represents a paradigm shift in management of
anemia in chronic hemodialysis patients.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
journals.org.
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